

Protalix BioTherapeutics, Inc.  
Form 8-K  
October 15, 2013

---

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): October 14, 2013**

---

**Protalix BioTherapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**

---

**Florida**  
**(State or other jurisdiction**  
**of incorporation)**

**001-33357**  
**(Commission File Number)**

**65-0643773**  
**(IRS Employer**  
**Identification No.)**



**Item 8.01. Other Events**

On October 14, 2013, Protalix BioTherapeutics, Inc. issued a press release announcing initial positive results from its phase I clinical trial of oral glucocerebrosidase (GCD), or Oral GCD (PRX-112), in patients with Gaucher disease. A copy of the press release is filed as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits**

**(d) Exhibits**

99.1 Press release dated October 14, 2013.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROTALIX  
BIOTHERAPEUTICS, INC.

Date: October 15, 2013 By: /s/ David Aviezer  
Name: David Aviezer, Ph.D.  
Title: President and  
Chief Executive Officer